Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

NCT01226719

Colorectal Cancer

COMPLETED PHASE2

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

NCT03635021

Colorectal Cancer

ACTIVE_NOT_RECRUITING PHASE3

Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer

NCT01288339

Metastatic Colorectal Cancer

COMPLETED PHASE2

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status

NCT03142516

Colorectal Neoplasms Colorectal Carcinoma Colorectal Cancer Metastatic +1 more

COMPLETED PHASE2

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

NCT01704703

Stage IV Colorectal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Panitumumab+FOLFOX 4

Group Type EXPERIMENTAL

Panitumumab+FOLFOX-4

Intervention Type DRUG

Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.

A cycle of panitumumab is defined as 14 days.

FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:

* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle
* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2
* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2
* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2

2

Panitumumab+FOLFIRI

Group Type EXPERIMENTAL

Panitumumab+FOLFIRI

Intervention Type DRUG

Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.

A cycle of panitumumab is defined as 14 days.

FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:

* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle
* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing
* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1
* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Panitumumab+FOLFOX-4

Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.

A cycle of panitumumab is defined as 14 days.

FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:

* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle
* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2
* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2
* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2

Intervention Type DRUG

Panitumumab+FOLFIRI

Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.

A cycle of panitumumab is defined as 14 days.

FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:

* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle
* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing
* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1
* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman \> 18 years \< 75 of age
* Competent to comprehend, sign, and date an IEC-approved informed consent form
* Histologically confirmed adenocarcinoma of the colon or rectum
* Wild Type KRAS status
* Metastatic colorectal carcinoma exclusively affecting only the liver, compliant with one of the following criteria

1. Number of liver metastasis ≥ 4.
2. Size of one liver metastasis \> 10 cm in diameter.
3. Liver metastases technically not resectable.
* At least 1 uni-dimensionally measurable lesion
* Patients with the following characteristics will be included:

1. Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or capecitabine +/- radiotherapy with a disease-free interval \> than 6 months after its completion; or after oxaliplatin containing adjuvant treatment with a disease-free interval \> than 12 months
2. Recurrence after surgical treatment and/or radiotherapy with no adjuvant systemic treatment.
3. De novo diagnosis of the disease.
* Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior chemotherapy.
* Prior radiotherapy is acceptable.
* Patients deemed to have no major contra-indication to liver surgery from a general health perspective.
* Karnofsky performance status ≥ 70%
* Adequate bone marrow function: neutrophils ≥ 1.5 x109/ L; platelets ≥ 100 x109/ L;hemoglobin ≥ 9g/ dL
* Hepatic and metabolic function as follows:

Total bilirubin count ≤ 1.5 x ULN and not increasing more than 25% within the last 4 weeks; ALAT and ASAT \< 5 x ULN;

* Renal function, calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.
* Magnesium \> LLN

Exclusion Criteria

* Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, erlotinib).Subjects who have experienced an infusion reaction to their first dose of anti-EGFR therapy (cetuximab) may participate in this clinical trial.
* Surgery (not including diagnostic biopsy) and/or radiotherapy in the 4 weeks prior to inclusion in the study.
* Metastasis on any site other than the liver, including extrahepatic lymph nodes.
* Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of the skin or pre-invasive carcinoma of the skin.
* Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion
* Unresolved toxicities from prior systemic therapy that, in the opinion of the investigator, does not qualify the patient for inclusion
* Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia
* History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan
* Treatment for systemic infection within 14 days before initiating study treatment
* Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as \> 4 loose stools per day)
* History of Gilbert's syndrome or dihydropyrimidine deficiency
* History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results
* Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
* subject allergic to the ingredients of the study medication or to Staphylococcus protein A
* Any co-morbid disease that would increase risk of toxicity
* Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures
* Any investigational agent within 30 days before enrolment
* Must not have had a major surgical procedure within 28 days of randomization
* Subject who is pregnant or breast feeding
* Woman or man of childbearing potential not consenting to use adequate contraceptive precautions i.e. double barrier contraceptive methods (eg diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last study drug administration for women, and 1 month for men
* Subject unwilling or unable to comply with study requirements

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No